|
Everolimus (INN) (earlier code name RAD001) is the 40-''O''-(2-hydroxyethyl) derivative of sirolimus and works similarly to sirolimus as an inhibitor of mammalian target of rapamycin (mTOR). It is currently used as an immunosuppressant to prevent rejection of organ transplants and treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers. It is marketed by Novartis under the tradenames Zortress (USA) and Certican (Europe and other countries) in transplantation medicine, and Afinitor in oncology. Everolimus also available with Biocon with the brand name of ''Evertor''. ==Approvals and indications== Everolimus is approved for various conditions: * Advanced kidney cancer (approved in March 2009) * Prevention of organ rejection after renal transplant(April 2010) * Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) in patients who are not suitable for surgical intervention (October 2010) * Progressive or metastatic pancreatic neuroendocrine tumors not surgically removable (May 2011)〔http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm254350.htm〕 * Breast cancer in post-menopausal women with advanced hormone-receptor positive, HER2-negative type cancer, in conjunction with exemestane (July 2012) * Prevention of organ rejection after liver transplant(Feb 2013) 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Everolimus」の詳細全文を読む スポンサード リンク
|